多发性-话题@MedSci

#多发性#

905篇内容 | 2932人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1890314, encodeId=f1371890314cc, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, objectTitle=JNNP：多发性硬化症患者对SARS-CoV-2 mRNA疫苗的体液免疫, objectType=article, longId=219212, objectId=25c4219212b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25c4219212b0, replyNumber=0, likeNumber=64, createdTime=2022-02-28, rootId=0, userName=jml2009, userId=04d6114, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25c4219212b0, moduleTitle=JNNP：多发性硬化症患者对SARS-CoV-2 mRNA疫苗的体液免疫, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=25c4219212b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1890337, encodeId=7804189033e11, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, objectTitle=Haematologica：Isatuximab 加卡非佐米和地塞米松与卡非佐米和地塞米松在肾功能不全的复发性多发性骨髓瘤患者中的比较, objectType=article, longId=292200, objectId=8c42292200d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8c42292200d9, replyNumber=0, likeNumber=73, createdTime=2022-06-17, rootId=0, userName=jml2009, userId=04d6114, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8c42292200d9, moduleTitle=Haematologica：Isatuximab 加卡非佐米和地塞米松与卡非佐米和地塞米松在肾功能不全的复发性多发性骨髓瘤患者中的比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8c42292200d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1890298, encodeId=b4e41890298e6, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, objectTitle=Neurology：多发性硬化症患者结直肠癌生存率, objectType=article, longId=217263, objectId=19d921e2630a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=19d921e2630a, replyNumber=0, likeNumber=86, createdTime=2021-12-02, rootId=0, userName=jml2009, userId=04d6114, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=19d921e2630a, moduleTitle=Neurology：多发性硬化症患者结直肠癌生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=19d921e2630a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1890297, encodeId=8d45189029e0d, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, objectTitle=J Clin Oncol：新确诊的多发性骨髓瘤患者的巩固和维持治疗, objectType=article, longId=217223, objectId=cc2f21e223a1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cc2f21e223a1, replyNumber=0, likeNumber=102, createdTime=2022-07-20, rootId=0, userName=jml2009, userId=04d6114, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cc2f21e223a1, moduleTitle=J Clin Oncol：新确诊的多发性骨髓瘤患者的巩固和维持治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cc2f21e223a1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1890285, encodeId=680e1890285db, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, objectTitle=J Clin Oncol：Venetoclax+达雷木单抗+地塞米松±硼替佐米可有效治疗复发/难治性多发性骨髓瘤！, objectType=article, longId=215765, objectId=00d1215e657e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=00d1215e657e, replyNumber=0, likeNumber=81, createdTime=2022-01-17, rootId=0, userName=jml2009, userId=04d6114, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=00d1215e657e, moduleTitle=J Clin Oncol：Venetoclax+达雷木单抗+地塞米松±硼替佐米可有效治疗复发/难治性多发性骨髓瘤！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=00d1215e657e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1890346, encodeId=142e1890346d3, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, objectTitle=AJH：使用泊马度胺和地塞米松±皮下达雷妥尤单抗治疗的复发/难治性多发性骨髓瘤患者的健康相关生活质量——来自 APOLLO 试验的患者报告结果, objectType=article, longId=295313, objectId=f5062953135a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f5062953135a, replyNumber=0, likeNumber=69, createdTime=2022-03-27, rootId=0, userName=jml2009, userId=04d6114, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f5062953135a, moduleTitle=AJH：使用泊马度胺和地塞米松±皮下达雷妥尤单抗治疗的复发/难治性多发性骨髓瘤患者的健康相关生活质量——来自 APOLLO 试验的患者报告结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f5062953135a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1890380, encodeId=ad781890380fd, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, objectTitle=J Clin Oncol：Ciltacabtagene autoleucel治疗复发/难治性多发性骨髓瘤的长期预后, objectType=article, longId=728872, objectId=66cae28872f3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=66cae28872f3, replyNumber=0, likeNumber=98, createdTime=2022-10-21, rootId=0, userName=jml2009, userId=04d6114, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=66cae28872f3, moduleTitle=J Clin Oncol：Ciltacabtagene autoleucel治疗复发/难治性多发性骨髓瘤的长期预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=66cae28872f3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1890323, encodeId=7acc1890323b4, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, objectTitle=JNNP:多发性硬化诊断中的视网膜眼间差异和萎缩进展, objectType=article, longId=220260, objectId=f24c22026075, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f24c22026075, replyNumber=0, likeNumber=83, createdTime=2021-12-20, rootId=0, userName=jml2009, userId=04d6114, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f24c22026075, moduleTitle=JNNP:多发性硬化诊断中的视网膜眼间差异和萎缩进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f24c22026075)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1890315, encodeId=bc631890315c2, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, objectTitle=Lancet Neurol：耐受性差，疗效阴性——不推荐贝沙罗汀治疗复发缓解型多发性硬化症(CCMR ONE), objectType=article, longId=219155, objectId=f5c7219155cb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f5c7219155cb, replyNumber=0, likeNumber=60, createdTime=2022-02-19, rootId=0, userName=jml2009, userId=04d6114, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f5c7219155cb, moduleTitle=Lancet Neurol：耐受性差，疗效阴性——不推荐贝沙罗汀治疗复发缓解型多发性硬化症(CCMR ONE), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f5c7219155cb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1890342, encodeId=2934189034240, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, objectTitle=Neural Regen Res：复发-缓解型多发性硬化症的海马结构、功能连接与认知功能、残疾程度有关, objectType=article, longId=293877, objectId=ffe42938e753, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ffe42938e753, replyNumber=0, likeNumber=0, createdTime=2022-03-30, rootId=0, userName=jml2009, userId=04d6114, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ffe42938e753, moduleTitle=Neural Regen Res：复发-缓解型多发性硬化症的海马结构、功能连接与认知功能、残疾程度有关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ffe42938e753)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1890351, encodeId=b2ec1890351e2, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, objectTitle=Lancet Oncol：泊马度胺-地塞米松方案加用Isatuximab可显著延长复发/难治性多发性骨髓瘤患者的总生存期, objectType=article, longId=295593, objectId=ab9629559335, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ab9629559335, replyNumber=0, likeNumber=73, createdTime=2022-09-04, rootId=0, userName=jml2009, userId=04d6114, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ab9629559335, moduleTitle=Lancet Oncol：泊马度胺-地塞米松方案加用Isatuximab可显著延长复发/难治性多发性骨髓瘤患者的总生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ab9629559335)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1890294, encodeId=8c4e18902948d, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, objectTitle=JNER:多发性硬化症、帕金森病患者和健康对照者的实验室步态特征与日常生活步态特征, objectType=article, longId=216961, objectId=e940216961e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e940216961e2, replyNumber=0, likeNumber=96, createdTime=2022-01-05, rootId=0, userName=jml2009, userId=04d6114, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e940216961e2, moduleTitle=JNER:多发性硬化症、帕金森病患者和健康对照者的实验室步态特征与日常生活步态特征, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e940216961e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1890284, encodeId=3af7189028429, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, objectTitle=Lancet：双特异性抗体Teclistamab有望成为复发性/难治性多发性骨髓瘤的新疗法！, objectType=article, longId=215591, objectId=5479215591c2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5479215591c2, replyNumber=0, likeNumber=68, createdTime=2021-10-06, rootId=0, userName=jml2009, userId=04d6114, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5479215591c2, moduleTitle=Lancet：双特异性抗体Teclistamab有望成为复发性/难治性多发性骨髓瘤的新疗法！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5479215591c2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1890280, encodeId=90f11890280ee, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, objectTitle=Blood：卡非佐米、来那度胺和地塞米松联合骨髓移植可有效治疗多发性骨髓瘤！, objectType=article, longId=214610, objectId=ac80214610c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ac80214610c6, replyNumber=0, likeNumber=93, createdTime=2022-02-12, rootId=0, userName=jml2009, userId=04d6114, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ac80214610c6, moduleTitle=Blood：卡非佐米、来那度胺和地塞米松联合骨髓移植可有效治疗多发性骨髓瘤！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ac80214610c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1890259, encodeId=81c91890259f3, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, objectTitle=JAMA Neurol：血清N-乙酰氨基葡萄糖或是多发性硬化疾病进展的重要标志物, objectType=article, longId=212163, objectId=c37a21216340, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c37a21216340, replyNumber=0, likeNumber=80, createdTime=2022-02-20, rootId=0, userName=jml2009, userId=04d6114, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c37a21216340, moduleTitle=JAMA Neurol：血清N-乙酰氨基葡萄糖或是多发性硬化疾病进展的重要标志物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c37a21216340)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1890362, encodeId=f2f1189036251, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, objectTitle=多发性骨髓瘤治疗中遇上不良反应怎么办？, objectType=article, longId=301124, objectId=739f301124b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=739f301124b4, replyNumber=0, likeNumber=81, createdTime=2022-10-05, rootId=0, userName=jml2009, userId=04d6114, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=739f301124b4, moduleTitle=多发性骨髓瘤治疗中遇上不良反应怎么办？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=739f301124b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1890276, encodeId=0d8c18902e605, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, objectTitle=Ann Neurol-脑脊液骨髓微泡，可有效预测多发性硬化预后, objectType=article, longId=214313, objectId=c52421431351, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c52421431351, replyNumber=0, likeNumber=69, createdTime=2022-03-03, rootId=0, userName=jml2009, userId=04d6114, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c52421431351, moduleTitle=Ann Neurol-脑脊液骨髓微泡，可有效预测多发性硬化预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c52421431351)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1890352, encodeId=9f5e189035213, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, objectTitle=Annals of Neurology：复发缓解型多发性硬化，认知功能如何随时间变化？, objectType=article, longId=295547, objectId=546b29554ebb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=546b29554ebb, replyNumber=0, likeNumber=66, createdTime=2022-09-13, rootId=0, userName=jml2009, userId=04d6114, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=546b29554ebb, moduleTitle=Annals of Neurology：复发缓解型多发性硬化，认知功能如何随时间变化？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=546b29554ebb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1890293, encodeId=87c518902936f, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, objectTitle=Neurology：Occrelizumab在不同类型的多发性硬化症患者中的安全性, objectType=article, longId=216853, objectId=451721685336, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=451721685336, replyNumber=0, likeNumber=74, createdTime=2022-04-23, rootId=0, userName=jml2009, userId=04d6114, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=451721685336, moduleTitle=Neurology：Occrelizumab在不同类型的多发性硬化症患者中的安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=451721685336)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1890365, encodeId=703b1890365a0, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, objectTitle=四管血，“看”出了一例多发性骨髓瘤, objectType=article, longId=302075, objectId=2a2b3020e59f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2a2b3020e59f, replyNumber=0, likeNumber=67, createdTime=2022-07-08, rootId=0, userName=jml2009, userId=04d6114, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2a2b3020e59f, moduleTitle=四管血，“看”出了一例多发性骨髓瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2a2b3020e59f)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

多发性

2020-05-29

jml2009 (审核中...)

前往app查看评论内容

#多发性#

JNNP：多发性硬化症患者对SARS-CoV-2 mRNA疫苗的体液免疫

2022-02-28

jml2009 (审核中...)

前往app查看评论内容

#多发性#

Haematologica：Isatuximab 加卡非佐米和地塞米松与卡非佐米和地塞米松在肾功能不全的复发性多发性骨髓瘤患者中的比较

2022-06-17

jml2009 (审核中...)

前往app查看评论内容

#多发性#

Neurology：多发性硬化症患者结直肠癌生存率

2021-12-02

jml2009 (审核中...)

前往app查看评论内容

#多发性#

J Clin Oncol：新确诊的多发性骨髓瘤患者的巩固和维持治疗

2022-07-20

jml2009 (审核中...)

前往app查看评论内容

#多发性#

J Clin Oncol：Venetoclax+达雷木单抗+地塞米松±硼替佐米可有效治疗复发/难治性多发性骨髓瘤！

2022-01-17

jml2009 (审核中...)

前往app查看评论内容

#多发性#

AJH：使用泊马度胺和地塞米松±皮下达雷妥尤单抗治疗的复发/难治性多发性骨髓瘤患者的健康相关生活质量——来自 APOLLO 试验的患者报告结果

2022-03-27

jml2009 (审核中...)

前往app查看评论内容

#多发性#

J Clin Oncol：Ciltacabtagene autoleucel治疗复发/难治性多发性骨髓瘤的长期预后

2022-10-21

jml2009 (审核中...)

前往app查看评论内容

#多发性#

JNNP:多发性硬化诊断中的视网膜眼间差异和萎缩进展

2021-12-20

jml2009 (审核中...)

前往app查看评论内容

#多发性#

Lancet Neurol：耐受性差，疗效阴性——不推荐贝沙罗汀治疗复发缓解型多发性硬化症(CCMR ONE)

2022-02-19

jml2009 (审核中...)

前往app查看评论内容

#多发性#

Neural Regen Res：复发-缓解型多发性硬化症的海马结构、功能连接与认知功能、残疾程度有关

2022-03-30

jml2009 (审核中...)

前往app查看评论内容

#多发性#

Lancet Oncol：泊马度胺-地塞米松方案加用Isatuximab可显著延长复发/难治性多发性骨髓瘤患者的总生存期

2022-09-04

jml2009 (审核中...)

前往app查看评论内容

#多发性#

JNER:多发性硬化症、帕金森病患者和健康对照者的实验室步态特征与日常生活步态特征

2022-01-05

jml2009 (审核中...)

前往app查看评论内容

#多发性#

Lancet：双特异性抗体Teclistamab有望成为复发性/难治性多发性骨髓瘤的新疗法！

2021-10-06

jml2009 (审核中...)

前往app查看评论内容

#多发性#

Blood：卡非佐米、来那度胺和地塞米松联合骨髓移植可有效治疗多发性骨髓瘤！

2022-02-12

jml2009 (审核中...)

前往app查看评论内容

#多发性#

JAMA Neurol：血清N-乙酰氨基葡萄糖或是多发性硬化疾病进展的重要标志物

2022-02-20

jml2009 (审核中...)

前往app查看评论内容

#多发性#

多发性骨髓瘤治疗中遇上不良反应怎么办？

2022-10-05

jml2009 (审核中...)

前往app查看评论内容

#多发性#

Ann Neurol-脑脊液骨髓微泡，可有效预测多发性硬化预后

2022-03-03

jml2009 (审核中...)

前往app查看评论内容

#多发性#

Annals of Neurology：复发缓解型多发性硬化，认知功能如何随时间变化？

2022-09-13

jml2009 (审核中...)

前往app查看评论内容

#多发性#

Neurology：Occrelizumab在不同类型的多发性硬化症患者中的安全性

2022-04-23

jml2009 (审核中...)

前往app查看评论内容

#多发性#

四管血，“看”出了一例多发性骨髓瘤

2022-07-08

科室
- - 订阅+
  - 更多科室
工具
服务